Matt Bryson, Wedbush semis analyst, joins 'Squawk on the Street' to discuss if the DeepSeek news impacts Bryson's thesis on U.S. semiconductor companies.

The tech sell-off caused by the release of China's DeepSeek's R1 large language model and subsequent concerns over the cost ...

Chinese startup DeepSeek has debuted an AI app that challenges OpenAI's ChatGPT and other U.S. rivals, sending a shock ...

Dan Ives is not alone in selecting Nvidia as a top stock pick for 2025. Harsh Kumar at Piper Sandler recently wrote, "We are ...

Palantir's AI dominance gains momentum as Wedbush boosts its price target, citing government tailwinds and enterprise ...

Wedbush analyst Robert Driscoll reiterated a Hold rating on Zentalis Pharmaceuticals (ZNTL – Research Report) today and set a price target of ...

Wedbush analyst Daniel Ives raised the firm’s price target on Oklo (OKLO) to $45 from $26 and keeps an Outperform rating on the shares as the ...

Wedbush initiated coverage of Rocket Pharmaceuticals (RCKT) with an Outperform rating and $32 price target The analyst believes 2025 “should be an inflection year” for Rocket with multiple ...

Wedbush Securities hiked its base case price target on Tesla (NASDAQ:TSLA) to $550 from $515 on its view that the golden age ...

Investing.com -- Wedbush Securities raised its price target for Palantir Technologies (NASDAQ: PLTR) to $90 per share in a ...

Analysts at Piper Sandler and Wedbush were among the teams raising their 12-month price targets this week, with Piper Sandler ...

Wedbush reduced their FY2024 earnings per share estimates for shares of Neurocrine Biosciences in a report released on ...